Researchers have revealed blood lactate is a key biomarker that can predict physical outcomes and prognosis in patients with ALS, the most common form of motor neurone disease.
(Photo credit: The 2R Artificiality / Adobe )
Key points
- Lactate is an essential metabolic fuel and has long been known to influence motor neuron survival
- Researchers have now confirmed revealed blood lactate is a key biomarker that can predict physical outcomes and prognosis in patients with Amyotrophic Lateral Sclerosis (ALS)
- The findings could inform treatment and care to help ALS patients retain weight and survive for longer
A study at The University of Queensland and Japan's Shiga University of Medical Science has revealed blood lactate is a key biomarker that can predict physical outcomes and prognosis in patients with ALS.
ALS - or Amyotrophic Lateral Sclerosis - is the most common form of motor neurone disease (MND) and gradually and inevitably erodes a person's ability to control voluntary muscle and movement, and to breathe on their own.
Shiga University neurologist Dr Ryutaro Nakamura said the findings could inform treatment and care to help ALS patients retain weight and survive for longer.
Dr Ryutaro Nakamura has been seconded to the MND-focused lab led by UQ's Associate Professor Shyuan Ngo at the Australian Institute for Bioengineering and Nanotechnology and UQ School of Biomedical Sciences .
(Photo credit: The Unviersity of Queensland)
"Lactate is an essential metabolic fuel and has long been known to influence motor neuron survival," Dr Nakamura said.
"This includes supporting the metabolic demands associated with ALS.
"Simply put, the more lactate an ALS patient has in their blood, the more likely they are to maintain weight and have a better prognosis."
Dr Nakamura's initial research at Shiga University alongside Professor Makoto Urushitani focused on a Japanese patient cohort.
It was expanded when Dr Nakamura was seconded to the MND-focused lab led by UQ's Associate Professor Shyuan Ngo at the Australian Institute for Bioengineering and Nanotechnology and UQ School of Biomedical Sciences .
In collaboration with UQ Associate Professor Frederik Steyn , researchers monitored 146 ALS patients in Japan and Australia to demonstrate those with low blood lactate levels began losing weight progressively after 3 months.
Associate Professor Shyuan Ngo (pictured right with Dr Ryutaro Nakamura) runs an MND-focused lab at UQ that examines the metabolic factors underpinning the disease.
(Photo credit: The University of Queensland)
"Our findings support the hypothesis that lower lactate levels are associated with an increased likelihood of weight loss in ALS patients, faster disease progression and earlier death," Dr Ngo said.
Dr Nakamura said the inclusion of an Australian ALS cohort and input from Dr Ngo and Dr Steyn strengthened the work and had provided critical international validation.
"Including both Australian and Japanese patients shows that the correlation between blood lactate levels, weight loss, and ALS prognosis transcends race and environment," Dr Nakamura said.
Dr Nakamura hoped the research would inform proactive nutritional support for ALS patients with low blood lactate levels and contribute to the development of new treatments.
"Because weight loss strongly predicts survival in ALS, patients with low lactate levels may benefit from early and intensive nutritional support to improve outcomes," Dr Nakamura said.
The research was published in the Annals of Neurology.
